Australia-based Genetic Technologies (GTG) plans to launch what it claims to be the world’s first comprehensive risk assessment test for breast and ovarian cancer.
The new test will analyse a patient’s risk of developing breast and/or ovarian cancer either from a hereditary genetic mutation or from sporadic or familial cancers, which are far more common.
The test offers a comprehensive risk assessment, including other clinical risk factors, in a simple saliva test.
Genetic stated that its new test integrates the patented GeneType platform for both breast and ovarian cancer. This allows 13 major ‘actionable’ susceptibility genes for breast and ovarian cancer to be detected on the platform.
The new GeneType test platform is expected to address patients older than 30 years of age who are at greater risk of developing breast and/or ovarian cancer.
Furthermore, the test will provide a higher classification rate of patients who have an elevated risk for breast and ovarian cancer compared with conventional clinical tools.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The company claims that this will be achieved by evaluating breast and ovarian cancer susceptibility from both rare and common genetic variants as well as other known clinical risk factors related to the development of both diseases.
GTG’s comprehensive risk assessment for both cancers can be carried out using a single saliva sample and a brief questionnaire.
GTG CEO Simon Morriss said: “GTG believes this Comprehensive Risk Test for Breast and Ovarian Cancer is one of our most important and significant contributions to the advancement of population-based genetic testing.
“We are moving beyond rare cancer-susceptibility genetics. We can look for the needle in the haystack, but we are also able to look at the haystack itself. Our non-invasive risk assessment test will address cancer risk at a population health level.”
The firm said the comprehensive risk assessment test will be clinically validated and have approval from an appropriate regulator.